ABSTRACT: The Rotterdam criteria for polycystic ovary syndrome (PCOS) are used by a wide range of medical professionals and researchers. However, the development of these criteria was based on expert meetings and not on evidence-based treatment guidance. Over the last decade, the Rotterdam criteria have been useful in guiding research, and a number of clinical studies on PCOS have been published consequently. We plead to revisit the Rotterdam criteria based on the available evidence in prognostic studies and randomized controlled trials. In this opinion paper, we provide arguments of the strengths and limitations of the Rotterdam criteria in guiding treatment selections and predicting prognoses in women with infertility. While the Rotterdam criteria have shown their advantages in predicting reproductive prognosis, the next step is to evaluate whether they can guide treatment choices in infertility as well as other health aspects of the syndrome. Based on available data in clinical studies, we should be able to determine whether the Rotterdam criteria are evidence-based criteria.
Introduction
Diagnosis (Greek διαγιγνωσκειν, to distinguish or discern) is the ascription of a name to an illness and implies the distinction of illness or disease from health (Pearce, 2011) . Diagnostic criteria for a certain disease or syndrome are composed of a collection of symptoms and signs, as well as biochemical, genetic, imaging and pathological findings. Diagnostic criteria help to classify a disease as present or absent and have several purposes. First, they aim to estimate the natural course of disease, which is important information for the person involved. Subsequently, and more importantly, when a diagnosis indicates that the natural course of a disease is expected to be suboptimal, diagnostic criteria can guide treatment decisions, which have to aim to modify this prognosis in a beneficial way, thus improving the outcomes for the patients.
These rules should also be applied to polycystic ovary syndrome (PCOS). Stein and Leventhal (1935) reported a series of seven women with polycystic ovaries and oligo/amenorrhoea, later to be known as PCOS. The chief complaints of these women were oligo/amenorrhoea with subfertility, hirsutism or lower abdominal pain. Out of the seven women in the report, five were infertile, three were obese and three had hirsutism. All the seven women in the report gained normal menstruation after wedge resection and two of them became pregnant (Stein and Leventhal, 1935) . Thus, the initial diagnosis of polycystic ovaries was related to patients' outcomes. Stein and Leventhal (1935) diagnosed polycystic ovaries with pneumoroentgenography and laparotomy. These diagnostic methods were abandoned with the advent of hormonal assays in the 1970s (Yen et al., 1970; Rebar et al., 1976; Yen, 1980) and the introduction of high-resolution real-time ultrasonography in the 1980s (Swanson et al., 1981; Adams et al., 1985) .
In 1990, the first international conference of PCOS was held at National Institutes of Health (NIH). Based on a consensus questionnaire of the attendees, rather than clinical research data, the following diagnostic criteria were put forth: oligo-anovulation and hyperandrogenism/hyperandrogenaemia in the absence of all other endocrinopathies (Zawadzki and Dunaif, 1992) . In 2003, a group of experts expanded the diagnostic criteria to include polycystic ovaries seen at ultrasound as a third diagnostic marker and to allow for a diagnosis of PCOS if two of the three criteria were met and the same endocrinopathies were excluded; these are known as the Rotterdam criteria (Azziz, 2006; Franks, 2006) and the Androgen Excess Society (AES) has proposed a new set of diagnostic criteria in 2006 , they are still the most widely adopted criteria by different guidelines (Vause et al., 2010; Teede et al., 2011; Legro et al., 2013) and are used by a wide range of obstetricians and gynaecologists as well as other specialists.
Do the Rotterdam Criteria Guide Treatment Selections?
Oligo-anovulatory infertile women with PCOS are treated with lifestyle intervention, medical or surgical ovulation induction and eventually IVF (Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008). Oligo-anovulation, with or without hyperandrogenism/ hyperandrogenaemia or polycystic ovarian morphology (PCOM), will not affect clinical decision-making in ovulation induction treatment choices according to current guidelines (Legro et al., 2013 In contrast, the World Health Organization (WHO) classification of anovulation is more pragmatic for guiding treatment selection. Based on a preliminary classification published in 1968 (Insler et al., 1968) , the WHO classified anovulinto three groups (World Health Organisation, 1973) 
Do the Rotterdam Criteria Predict Prognosis?
Predictive models for pregnancy outcomes in infertile women with WHO group II anovulation and PCOS have been reported (Imani et al., 1998 (Imani et al., , 2000 (Imani et al., , 2002 Mulders et al., 2003; van Wely et al., 2005; Rausch et al., 2009; Kuang et al., 2015) . In WHO-II anovulatory women treated with clomiphene, predicting factors for live birth include free androgen index (FAI), BMI, oligomenorrhoea and age (Imani et al., 2002) , while predictors for ovulation include FAI, BMI, oligomenorrhoea and mean ovarian volume (Imani et al., 1998 (Imani et al., , 2000 . Serum insulin-like growth factor-I (IGF-I), testosterone, age (Mulders et al., 2003) , oligomenorrhoea, duration of infertility and FAI (van Wely et al., 2005) can predict the chance of ongoing pregnancy in women treated with FSH. More recently, the predicting value of patient characteristics such as age, BMI, hirsutism score, FAI, insulin and duration of infertility on reproductive outcomes in women with PCOS have been further confirmed in the data of the PPCOSI and PPCOSII trials (Rausch et al., 2009; Kuang et al., 2015) .
The predicting factors in these models consist of different baseline characteristics. Some of them, such as hirsutism score, FAI, ovarian volume and oligomenorrhoea are important components of the Rotterdam criteria. Therefore, the different phenotypes of PCOS and the different components of the Rotterdam criteria can help to predict the reproductive outcomes to some extent, although other predictors (e.g. insulin) are not included in the Rotterdam criteria. These predicting factors need to be confirmed in different populations in future studies.
Existing biochemical tests for PCOS have poor sensitivity and specificity (Iliodromiti et al., 2013) . Anti-Müllerian hormone (AMH), a hormone produced by granulosa cells of ovarian follicles during the early stages (Broer et al., 2014) , is a promising biomaker for PCOS. AMH may be a good substitute for PCOM (Dewailly et al., 2011; Eilertsen et al., 2012) and also a useful initial diagnostic test for PCOS (Iliodromiti et al., 2013) . However, AMH is not included in the Rotterdam criteria.
Infertility is a Tip of the Iceberg in PCOS
In the above arguments, we exclusively focused on anovulatory infertility. For couples with anovulatory infertility, the current WHO-based classification can help clinicians guide treatment. We believe that in a similar way it should be evaluated whether the criteria that are used to diagnose PCOS can be used to guide treatment choices. The Rotterdam criteria have shown their advantages in predicting reproductive outcomes in women PCOS. The next step is to discover whether the criteria can guide clinical decision-making on treatment selections. With the introduction of individual participant data (IPD) meta-analysis to this area, it could be possible to solve this problem based on the IPD in previously published randomized controlled trials (RCTs). Additionally, this should also be the subject of future RCTs, in which not only a treatment effect is assessed in a dichotomous way, but there is also an evaluation of whether a treatment effect is dependent on baseline characteristics (Janes et al., 2011) .
Apart from infertility, it is clear that women fulfilling the PCOS criteria are at increased risks of pregnancy complications, long-term cardiovascular disease and endometrial cancer (Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 2012). However, it is unclear which component of the PCOS criteria are specifically related to these risks. As such, there is a need for more prognostic studies that indicate which of the PCOS criteria are predictive for these complications, as well as RCTs that evaluate which characteristics of PCOS women can be used as treatment selection markers. IPD meta-analyses on these aspects of PCOS are also necessary for future research, as these studies can guide researchers and clinicians to find target populations for different interventions and therefore provide evidence of personalized PCOS care.
While current criteria for PCOS are based on expert meetings, we plead to revisit them based on the evidence in prognostic studies and RCTs. The Rotterdam criteria have been useful in guiding research and therefore a number of clinical studies have been published over the past decade, but they should be evaluated for both prognostic capacity and the capacity to guide treatment.
Conclusions
As with many other complex syndromes, PCOS does not have a single diagnostic marker to provide a gold standard for reference. The consensus-based diagnostic criteria for PCOS in the Rotterdam criteria have defined the disease and, as such, have been valuable both clinically and scientifically. Although the Rotterdam criteria were developed based on expert opinions, research evidence has shown their advantages in predicting reproductive outcomes. As a next step, they should be evaluated for their capacity to guide treatment. We then could revisit these criteria based on both prognostic characteristics and treatment selection markers. This should guide the future status of the Rotterdam criteria for PCOS as to whether they are evidence-based criteria.
